3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
4
Active not recruiting
3
Recruiting
2
Unknown
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Pancreatic Neoplasms
29
Breast Neoplasms
21
Carcinoma, Non-Small-Cell Lung
20
Triple Negative Breast Neoplasms
15
Lung Neoplasms
10
Colorectal Neoplasms
8
Neoplasm Metastasis
7
Esophageal Squamous Cell Carcinoma
7
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Esophageal Neoplasms
5
Ovarian Neoplasms
4
Biliary Tract Neoplasms
4
Head and Neck Neoplasms
3
Gallbladder Neoplasms
3
Fallopian Tube Neoplasms
3
Carcinoma, Pancreatic Ductal
3
Vaccinia
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms by Site
2
Neoplasms
2
Locally Advanced Pancreatic Cancer
2
Gastrointestinal Neoplasms
2
Endometrial Neoplasms
2
Brain Neoplasms
2
Advanced Solid Tumors
2
Adenocarcinoma
2
Ureteral Neoplasms
1
Thyroid Neoplasms
1
Squamous Non-small Cell Lung Cancer
1
Interventions
pembrolizumab
18
Paclitaxel
13
Carboplatin
10
Pemetrexed
4
Cisplatin
4
patritumab deruxtecan
3
Gemcitabine
3
Docetaxel
3
Capecitabine
3
Albumin-Bound Paclitaxel
3
Histamine H2 Antagonists
2
Histamine Antagonists
2
Dexamethasone
2
Acetaminophen
2
130-nm albumin-bound paclitaxel
2
trastuzumab deruxtecan
1
osimertinib
1
olaparib
1
liposomal doxorubicin
1
lenvatinib
1
enzalutamide
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Serotonin 5-HT3 Receptor Antagonists
1
Ramucirumab
1
Oxaliplatin
1
Neurokinin-1 Receptor Antagonists
1
Neoadjuvant Therapy
1
Levoleucovorin
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT06841354
2026-05-29
TroFuse-011
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,000 enrolled
NCT06312176
2026-05-22
MK-2870-010
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,200 enrolled